Conference Coverage
ASH 2020: Highlights in Research and Patient Care
Release Date: January 4, 2021
Expiration Date: January 3, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held from December 5th through 8th, 2020, is the world's premier event in hematology—both malignant and nonmalignant. Although the ASH Annual Meeting regularly features research that is key to improving patient care, keeping up with all the advances—and knowing how and when to apply them to the management of patients—can be difficult. This activity focuses on abstracts from ASH 2020 in acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma, with a focus on data that can potentially improve patient care, as well as insights from faculty on practice application.
Format
Abstracts and Expert Commentary
Learning Objectives
After completing this activity, participants should be better able to:
- Identify recently presented data across the cancer care continuum for major hematologic malignancies
- Apply strategies for the management and monitoring of patients with hematologic malignancies based on the most current efficacy and safety evidence
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Elias J. Jabbour, MD
- Professor, Department of Leukemia
- Division of Cancer Medicine
- MD Anderson Cancer Center
- Houston, Texas
Sagar Lonial, MD, FACP
- Chair and Professor
- Department of Hematology and Medical Oncology
- Anne and Bernard Gray Family Chair in Cancer
- Chief Medical Officer
- Winship Cancer Institute
- Emory University School of Medicine
- Atlanta, Georgia
Eunice S. Wang, MD
- Chief, Leukemia Service
- Medical Director, Chemotherapy/Infusion Clinic
- Director, Hematologic Procurement Shared Resource
- Professor of Oncology, Department of Medicine
- Roswell Park Comprehensive Cancer Institute
- Buffalo, New York
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 3, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by educational grants from Bristol-Myers Squibb, Karyopharm Therapeutics, Oncopeptides, and Servier Pharmaceuticals LLC.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Jabbour: principal investigator: AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Genentech, Pfizer, Spectrum Pharmaceuticals, Takeda.
Dr Lonial: board of directors: TG Therapeutics; investigator/advisory board: Bristol-Myers Squibb, Celgene, Janssen, Takeda; advisory board: AbbVie, Amgen, GlaxoSmithKline, Novartis.
Dr Wang: advisory board/speakers bureau: Pfizer, Stemline Therapeutics; advisory board: AbbVie, Arog Pharmaceuticals, Astellas, Bristol-Myers Squibb/Celgene, Genentech, Jazz, Kite, Macrogenics, PTC Therapeutics, Takeda; speakers bureau: Dava Oncology.
Ms Williams: speakers bureau: AstraZeneca.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Williams as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: January 4, 2021
Expiration date: January 3, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100420ASH